← Leaderboards
Elke Lipka
Tsrl, Inc.
$23,898,253
Attributed
$23,898,253
Total exposure
16
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.3M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,898,253 · 16
By mechanism
R44$19,888,331 · 6
R43$2,360,691 · 6
R41$1,153,738 · 2
U44$292,746 · 1
R03$202,747 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsToxicologyOralDrug KineticsEnsureDoseSafetyMedicalIn VivoSmall Business Innovation Research GrantDesignRattusFormulationPre-ClinicalAbsorptionResistanceUniversitiesClinical DevelopmentAcuteProduct DevelopmentSkinToxic EffectRouteProperty
Grant awards (36)
Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease$1,097,498
R44 · FY2025 · DK · contact PI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$999,975
R44 · FY2025 · AI · contact PI
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$999,765
R44 · FY2025 · AI · contact PI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$999,746
R44 · FY2024 · AI · contact PI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$998,663
R44 · FY2024 · AI · contact PI
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$997,670
R44 · FY2024 · AI · contact PI
Phase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy Subjects$292,746
U44 · FY2024 · AI · contact PI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$999,604
R44 · FY2023 · AI · contact PI
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$998,521
R44 · FY2023 · AI · contact PI
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis$643,779
R44 · FY2023 · GM · contact PI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$299,999
R44 · FY2023 · AI · contact PI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$999,862
R44 · FY2022 · AI · contact PI
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis$988,469
R44 · FY2022 · GM · contact PI
Novel, Safe, Efficacious Heparin Reversal$394,392
R43 · FY2022 · HL · contact PI
Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease$299,620
R43 · FY2022 · HD · contact PI
Microneedle Delivery of Zanamivir for Treatment of Influenza$952,176
R44 · FY2021 · AI · contact PI
Microneedle Delivery of Zanamivir for Treatment of Influenza$971,504
R44 · FY2020 · AI · contact PI
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections$270,047
R41 · FY2020 · AI · contact PI
Microneedle Delivery of Zanamivir for Treatment of Influenza$998,654
R44 · FY2019 · AI · contact PI
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$971,090
R44 · FY2019 · AI · contact PI
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections$299,733
R41 · FY2019 · AI · contact PI
New Prodrug Strategies for Cidofovir Designed for Mitigating First-Pass Metabolism$101,522
R03 · FY2019 · AI · contact PI
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$983,590
R44 · FY2018 · AI · contact PI
Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections$300,000
R41 · FY2018 · AI · contact PI
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections$284,761
R43 · FY2018 · AI · contact PI
New Prodrug Strategies for Cidofovir Designed for Mitigating First-Pass Metabolism$101,225
R03 · FY2018 · AI · contact PI
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$1,000,000
R44 · FY2017 · AI · contact PI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$999,700
R44 · FY2017 · AI · contact PI
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections$287,765
R43 · FY2017 · AI · contact PI
Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections$283,958
R41 · FY2017 · AI · contact PI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$990,162
R44 · FY2016 · AI · contact PI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$997,904
R44 · FY2015 · AI · contact PI
Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection$299,360
R43 · FY2015 · AI · contact PI
Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection$300,000
R43 · FY2014 · AI · contact PI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$297,046
R43 · FY2014 · AI · contact PI
Development of the orally delivered, non-absorbable ACE inhibitor enalaprilat for$197,747
R43 · FY2010 · DK · contact PI